Back to UNH
UNH Stock: Optum Growth, Valuation and Risks
$UNHNEUTRALHealthcare

UNH Stock: Optum Growth, Valuation and Risks

UnitedHealth closed at $407.46 on Friday, November 13, after its latest quarterly earnings beat estimates and Optum Rx expanded operating earnings despite lower prescription volumes. The outlook is balanced: earnings growth and analyst targets offer support, while revenue softness, industry pressures and execution risks remain important.

November 14, 202610 min read
Current Price
$407.46
+0.58%
Analyst Rating
Strong Buy
Price Target
$478.68
17.5% upside
P/E Ratio
23.26

Executive Summary

Investment Thesis: UnitedHealth combines a large health-benefits business with Optum’s pharmacy, care-delivery and technology operations. Its third-quarter 2026 earnings exceeded estimates, and Optum Rx delivered higher operating earnings despite declining prescription volumes. However, trailing revenue growth was slightly negative, healthcare costs and regulation remain difficult to forecast, and recent performance has not kept pace with the broader market over the two-year period in the supplied data. The available evidence supports a balanced rather than one-sided view.

Current Price: $407.46 as of Friday, November 13 | Key Metric: Forward P/E of 17.46 | Stance: NEUTRAL

U.S. equity markets are closed on Saturday, November 14. UNH’s reported Friday close was up $2.33, or 0.58%, from the previous close. The next regular trading session is Monday, November 16.

Company Overview

UnitedHealth Group is a diversified healthcare company operating through UnitedHealthcare, which provides health-benefit coverage, and Optum, which offers pharmacy services, care delivery and health technology. That combination gives the company multiple sources of revenue, but also exposes it to complex reimbursement rules, medical-cost trends and government oversight.

Key Products & Competitive Position

  • Core Business: Health insurance and benefits, alongside pharmacy, care and data services.
  • Key Products: Employer and individual coverage, Medicare and Medicaid plans, Optum Rx pharmacy-benefit services, and Optum health services and technology.
  • Competitive Moat: Scale, broad customer and provider relationships, claims and care-management data, and the ability to coordinate services across insurance and healthcare operations.

Recent Developments

Optum Rx is a focal point after third-quarter 2026 operating earnings rose 10.9% to $1.72 billion, even as prescription volumes declined. The reported improvement was supported in part by product and profitability mix, including biosimilars. The result suggests that operating earnings need not move in lockstep with prescription counts, though the durability of that mix benefit is an open question. A separate news article reported a 5% dividend increase, but the supplied data does not include the company’s full announcement or the new payment schedule.

Financial Snapshot

Market Cap$365.09B
P/E Ratio23.26
52-Week Range$255.97 - $461.62
Dividend Yield2.22%
EPS (TTM)$17.61
ROE16.35%

Some financial data providers show slightly different trailing EPS and return-on-equity figures. The snapshot above uses the supplied key metrics; other figures below are identified as provider-reported where relevant.

Revenue & Earnings Trends

The supplied financial snapshot reports trailing revenue of approximately $450.06 billion and revenue growth of -0.40%. That is a modest decline, not an acceleration in the top line. At the same time, the data provider reports earnings growth of 76.10% and quarterly earnings growth of 75.00%, indicating a substantial earnings rebound from the comparison period. Those growth rates can be affected by the base period and should not be treated as a guaranteed run rate.

For full-year 2026, the Zacks consensus estimate cited in the supplied research is $20.61 per share, implying 20.06% growth from the prior-year level. This is an analyst estimate, not confirmed company guidance. The company’s next reported quarter is scheduled for January 20, 2027, with a supplied EPS estimate of $2.28.

Balance Sheet Highlights

Provider data lists $28.55 billion in cash, $74.33 billion in total debt and $26.50 billion in free cash flow. That implies net debt of roughly $45.78 billion, while free cash flow provides a meaningful source of financial flexibility. The current ratio is 0.74 and the quick ratio is 0.66, both below 1.0; these measures merit context because insurers and healthcare businesses have operating models that differ from those of industrial companies. Reported debt-to-equity is 70.43%.

Valuation Analysis

Current Valuation Metrics

Forward P/E17.46vs Industry: 15.68
PEG Ratio1.03Growth-adjusted
EV/EBITDA14.47Historical comparison unavailable
P/S Ratio0.81vs Peers: comparable data unavailable

The forward P/E is above the 15.68 industry average cited by Zacks, while the PEG ratio near 1.0 relates the share valuation to expected earnings growth. Neither measure captures the possibility that earnings estimates may change. The P/S figure is an approximation using market capitalization divided by trailing revenue; the provider also reports enterprise value to revenue of 0.93, which is a different measure.

Historical Comparison

A reliable five-year valuation average was not supplied, so a precise comparison with that period cannot be made. Yahoo Finance’s cited snapshot gives a two-year average closing price of $375.26; the $407.46 Friday close is about 8.6% above that average. The same snapshot reports a negative 27.95% total return over two years, illustrating that a recent price relative to an average alone does not describe the full shareholder experience. Dividend reinvestment and the precise measurement dates also matter.

Fair Value Estimate

The analyst mean target provided is $478.68, about 17.5% above the Friday close, while the target range spans $380 to $531. A second supplied provider snapshot shows a mean of $476.16 and median of $490, so estimates are not fully consistent across sources. These targets are third-party forecasts, not a guaranteed fair value. A cash-flow valuation would depend heavily on medical-cost trends, margins, growth and discount-rate assumptions, none of which are detailed enough here to calculate a defensible independent DCF estimate.

Competitive Landscape

Market Position

Market Share: Not supplied; varies by product and customer segment | Ranking: Among the largest U.S. health-benefit and healthcare-services companies

Key Competitors

CVS Health (CVS)Aetna health plans, pharmacy services and retail healthcare operations
Elevance Health (ELV)Health benefits and care-management services, including government programs
The Cigna (CI)Health-benefit services and pharmacy operations through its Evernorth business

Competitive Advantages

  • Scale: A broad customer base and operating footprint can support administrative efficiency and negotiating reach.
  • Integrated operations: UnitedHealthcare and Optum participate in different parts of the healthcare system, creating opportunities to coordinate coverage, pharmacy and care services.
  • Data and relationships: Claims information, provider networks and established customer relationships can support service design and care management, though they also raise privacy and oversight responsibilities.

The same integration that differentiates UNH can draw scrutiny over conflicts of interest, pricing and market power. Competitors also span multiple business models, making simple market-share comparisons unreliable without segment-specific figures.

Earnings Track Record

Last 4 Quarters: 1 verified beat / 0 verified misses; 3 quarter results not supplied

Recent Earnings History

Q3 2026$4.69 vs $4.14 estBEAT
Q2 2026Actual and estimate not suppliedUNAVAILABLE
Q1 2026Actual and estimate not suppliedUNAVAILABLE
Q4 2025Actual and estimate not suppliedUNAVAILABLE

Guidance Trend

The available materials do not provide a sequence of management guidance revisions, so a trend in company-issued guidance cannot be verified. The cited $20.61 full-year 2026 EPS figure is a Zacks consensus estimate, and the January 20, 2027 report has a supplied estimate of $2.28 per share. Investors can compare reported results with those estimates when the next filing becomes available, while keeping analyst forecasts distinct from management commitments.

Analyst Sentiment

Consensus Rating: Strong Buy, according to the supplied analyst survey

Strong Buy: 6 Buy: 15 Hold: 5 Sell: 0

The supplied recommendation breakdown covers 26 analysts and lists no Sell or Strong Sell ratings. Yahoo Finance’s extracted snapshot instead lists 25 opinions and a mean recommendation described as Buy. Provider coverage and rating definitions can differ, so these counts should be read as a snapshot rather than a unanimous view.

Price Targets

  • Low: $380
  • Mean: $478.68 (+17.5% versus $407.46)
  • High: $531

Recent Analyst Actions

No specific recent rating changes were supplied. Zacks assigns UNH a Rank #2, labeled Buy, and cites a Value Score of A; those are the publication’s classifications, not an independent forecast. The gap between the $380 low target and $531 high target is substantial, highlighting uncertainty around the earnings outlook even though the survey’s average rating is positive.

Recent News & Catalysts

Key Developments

  • Optum Rx earnings and volume: Third-quarter operating earnings reportedly rose 10.9% to $1.72 billion despite declining prescription volumes. The durability of the improvement, including the contribution from biosimilars and product mix, remains a key operating question.
  • Dividend and relative performance: A November 12 article highlighted a reported 5% dividend increase and compared a ten-year hypothetical investment in UNH with the S&P 500. That comparison is commentary rather than a company operating update, but it underscores that dividend growth does not ensure market-level total returns.
  • Shareholder legal solicitation: A November 12 press release invited shareholders to contact a law firm about potential fiduciary-duty claims. A solicitation is not evidence that allegations are proven or that the company has been found liable; any eventual legal developments could nevertheless attract attention.

Upcoming Catalysts

Next Earnings: January 20, 2027, with supplied EPS estimate of $2.28 | Key Events: Quarterly medical-cost trends, Medicare and Medicaid policy updates, Optum Rx prescription volumes and margins, and any verified company guidance changes

The next earnings release is the clearest scheduled catalyst in the supplied calendar. Policy decisions and reimbursement updates can affect the business throughout the year, but no specific dates for those events were provided.

Technical Outlook

Current Price: $407.46 as of Friday, November 13 vs 52-Week High: $461.62 (11.7% below the high)

Trend Analysis

Friday’s $2.33 gain placed the close near the session high of $408.51, after a range of $400.50 to $408.51. The price remains about 59.2% above the 52-week low of $255.97, while still below the 52-week high. Those endpoints show a wide annual trading range, but moving averages, trading volume and momentum indicators were not supplied, limiting a fuller technical assessment.

Key Levels

  • Resistance: $408.51, the Friday session high, and $461.62, the 52-week high
  • Support: $400.50 to $405.13, spanning Friday’s low and the previous close, then $380, the low analyst target rather than a confirmed chart support level

These are reference points from the supplied price and target data, not a prediction that the stock will test them. Price action after the market reopens on Monday, November 16, may differ from Friday’s close.

Bull vs Bear Case

Bull Case

  • Earnings recovery: The latest supplied quarter beat estimates, and provider data shows strong year-over-year earnings growth, although the comparison period matters.
  • Optum contribution: Higher Optum Rx operating earnings amid lower prescription volumes suggest profitability can benefit from mix and execution, not volume alone.
  • Valuation and analyst view: The forward P/E is below the trailing P/E, and the analyst mean target is above the current quote. Both depend on estimates being realized and are not assured outcomes.

Bull Target: $531, the supplied analyst high target, approximately 30.3% above $407.46

Bear Case

  • Revenue softness: Supplied trailing revenue growth is -0.40%, and higher earnings growth may be difficult to sustain if revenue remains weak.
  • Healthcare cost and policy exposure: Medical utilization, reimbursement changes and government program rules can pressure margins or increase uncertainty.
  • Forecast risk: The analyst target range reaches $380, below the current price, while UNH’s reported two-year total return was negative in the cited data.

Bear Target: $380, the supplied analyst low target, approximately 6.7% below $407.46

The targets above are the endpoints of third-party analyst estimates, not forecasts made by this report. Which case gains credibility will depend on reported medical costs, Optum’s performance and whether earnings estimates remain intact.

Risks to Consider

  • Valuation Risk: A forward P/E of 17.46 is above the cited industry average of 15.68. If earnings estimates fall, the share valuation could be reassessed even without a major change in revenue.
  • Competitive Risk: Insurers, pharmacy-benefit managers and healthcare providers compete on price, networks and service. Changes in customer or provider relationships could affect retention and margins.
  • Macro Risk: Medical utilization, labor expenses, interest rates and public-program reimbursement can alter costs and cash flows. The company’s scale does not remove exposure to these factors.
  • Execution Risk: UNH must coordinate a complex set of insurance, pharmacy and care operations. Lower prescription volumes, pressure on Optum margins, system disruptions, privacy incidents or regulatory intervention could undermine expected earnings growth.

Investors also face data uncertainty: supplied analyst targets and provider snapshots differ, and three recent quarterly earnings comparisons were not included. That makes it important to verify figures against company filings and current market data before drawing conclusions.

Bottom Line

Investment Verdict: NEUTRAL

UNH has credible strengths in scale, cash generation and diversified healthcare operations, and its latest reported quarter provides evidence of earnings momentum. Yet modestly negative revenue growth, complex policy exposure and uncertainty around the durability of earnings gains temper the positive analyst consensus. This report is informational analysis, not investment advice or a personalized recommendation.

Action Items for Investors

  • Long-term investors: Track revenue alongside earnings, cash flow and segment margins to assess whether recent profit growth is broad-based and repeatable.
  • Short-term traders: Treat the Friday session range and annual high as reference levels only; the supplied data does not include enough volume or trend indicators to establish a complete technical signal.
  • Risk management: Account for the wide analyst-target range, healthcare policy exposure and the possibility that estimates change. This is a framework for monitoring risk, not a personal allocation instruction.

What to Watch This Week

  • UNH’s response to trading after the market reopens Monday, November 16, relative to Friday’s $400.50 to $408.51 session range.
  • Verified company or regulatory updates on Medicare, Medicaid, reimbursement and medical-cost trends.
  • Any additional detail on Optum Rx volumes, biosimilar contribution and the durability of operating earnings growth ahead of the January 20, 2027 earnings report.

Share this report

Share this article

Spread the word on social media

Think UNH will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.